Literature DB >> 20851495

Complement mediated hepatocytes injury in a model of autoantibody induced hepatitis.

Zhidan Tu1, Qing Li, Hong-Shiue Chou, Ching-Chuang Hsieh, Howard Meyerson, Marion G Peters, Hong Bu, John J Fung, Shiguang Qian, Lina Lu, Feng Lin.   

Abstract

Despite multiple reports on autoantibody-initiated complement activation in autoimmune hepatitis (AIH), how does the humoral immunity contribute to the pathogenesis of AIH remained unclear. In this report, by adoptively transferring a polyclonal rabbit anti-OVA antibody into Hep-OVA Tg mice in which OVA is selectively expressed on the surface of hepatocytes, we found that excessive complement activation initiated by the autoantibody overwhelmed the protection of intrinsic cell surface complement regulators, and induced hepatocytes injury both in vitro and in vivo. The anti-OVA antibody induced hepatic injury in Hep-OVA Tg but not WT C57BL/6 mice as assessed by serum ALT levels and liver histopathology. Immunohistochemical analyses showed that after the antibody administration, there was massive complement activation on anti-OVA IgG coated hepatocytes in Hep-OVA Tg mice, but not in WT mice. Consistent with these results, depleting complement by cobra venom factor (CVF) prior to antibody injections protected Hep-OVA Tg mice from anti-OVA IgG induced hepatic injury. In addition, treating Hep-OVA Tg mice with recombinant mouse decay accelerating factor, a native complement inhibitor, protected them from autoantibody induced hepatitis. These results suggest that complement could play a pivotal role in liver specific autoantibody mediated hepatocyte injury in AIH, and that complement inhibitors could be, in principle, developed as novel therapeutics against AIH.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851495      PMCID: PMC3557916          DOI: 10.1016/j.imbio.2010.08.004

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  34 in total

1.  Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.

Authors:  O B Spiller; O Criado-García; S Rodríguez De Córdoba; B P Morgan
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 2.  Autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Curr Opin Gastroenterol       Date:  2009-05       Impact factor: 3.287

3.  Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.

Authors:  Feng Lin; Henry J Kaminski; Bianca M Conti-Fine; Wei Wang; Chelliah Richmonds; M Edward Medof
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

4.  Activation of human complement by human lymphoid cells sensitized with histocompatibility alloantisera.

Authors:  S Ferrone; N R Cooper; M A Pellegrino; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

5.  Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.

Authors:  F Lin; Y Fukuoka; A Spicer; R Ohta; N Okada; C L Harris; S N Emancipator; M E Medof
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

6.  Bulk production and functional analyses of mouse CD55's native and deglycosylated active domains.

Authors:  F Lin; R M Immormino; M Shoham; M E Medof
Journal:  Arch Biochem Biophys       Date:  2001-09-01       Impact factor: 4.013

7.  Primary human hepatocytes are protected against complement by multiple regulators.

Authors:  Jarkko Halme; Michael Sachse; Heiko Vogel; Thomas Giese; Ernst Klar; Michael Kirschfink
Journal:  Mol Immunol       Date:  2009-05-14       Impact factor: 4.407

8.  A novel IgM class autoantibody to a hepatocyte-related 190 kDa molecule in patients with type 1 autoimmune hepatitis.

Authors:  Katsumi Yamauchi; Naoko Yamaguchi; Takaji Furukawa; Kazuko Takatsu; Toshimi Nakanishi; Mina Sasaki; Etsuko Isono; Katsutoshi Tokushige; Tatsuji Komatsu; Keiko Shiratori
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

9.  Bid activates multiple mitochondrial apoptotic mechanisms in primary hepatocytes after death receptor engagement.

Authors:  Yongge Zhao; Wen-Xing Ding; Ting Qian; Simon Watkins; John J Lemasters; Xiao-Ming Yin
Journal:  Gastroenterology       Date:  2003-09       Impact factor: 22.682

10.  Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

Authors:  M E Medof; T Kinoshita; V Nussenzweig
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  9 in total

1.  Mesenchymal stem cells are injured by complement after their contact with serum.

Authors:  Yan Li; Feng Lin
Journal:  Blood       Date:  2012-09-10       Impact factor: 22.113

2.  Circulating complement factor H levels are associated with disease severity and relapse in autoimmune hepatitis.

Authors:  Manabu Hayashi; Kazumichi Abe; Masashi Fujita; Atsushi Takahashi; Hideharu Sekine; Hiromasa Ohira
Journal:  JHEP Rep       Date:  2022-04-29

3.  Complement and the alternative pathway play an important role in LPS/D-GalN-induced fulminant hepatic failure.

Authors:  Shihui Sun; Yan Guo; Guangyu Zhao; Xiaojun Zhou; Junfeng Li; Jingya Hu; Hong Yu; Yu Chen; Hongbin Song; Fei Qiao; Guilian Xu; Fei Yang; Yuzhang Wu; Stephen Tomlinson; Zhongping Duan; Yusen Zhou
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

Review 4.  Toward a new autoantibody diagnostic orthodoxy: understanding the bad, good and indifferent.

Authors:  Marvin J Fritzler
Journal:  Auto Immun Highlights       Date:  2012-03-21

5.  Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H.

Authors:  Jun-Feng Li; Xiao-Peng Dai; Wei Zhang; Shi-Hui Sun; Yang Zeng; Guang-Yu Zhao; Zhi-Hua Kou; Yan Guo; Hong Yu; Lan-Ying Du; Shi-Bo Jiang; Yu-Sen Zhou
Journal:  MBio       Date:  2015-03-24       Impact factor: 7.867

6.  Expression of HLA and Autoimmune Pathway Genes in Liver Biopsies of Young Subjects With Autoimmune Hepatitis Type 1.

Authors:  Emilia Shin; Kathleen B Schwarz; Lorraine V Jones-Brando; Liliana D Florea; Sarven Sabunciyan; Laura Delong Wood; Robert H Yolken
Journal:  J Pediatr Gastroenterol Nutr       Date:  2022-06-27       Impact factor: 3.288

7.  Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview.

Authors:  Hind I Fallatah; Hisham O Akbar
Journal:  Autoimmune Dis       Date:  2012-12-12

8.  Complementary serum proteomic analysis of autoimmune hepatitis in mice and patients.

Authors:  Hongbin Li; Guoshun Li; Xinyu Zhao; Yongkang Wu; Wen Ma; Yuling Liu; Fengming Gong; Shufang Liang
Journal:  J Transl Med       Date:  2013-06-13       Impact factor: 5.531

9.  Presence of antibodies against self human leukocyte antigen class II molecules in autoimmune hepatitis.

Authors:  Satoshi Yamagiwa; Hiroteru Kamimura; Masaaki Takamura; Takuya Genda; Takafumi Ichida; Minoru Nomoto; Yutaka Aoyagi
Journal:  Int J Med Sci       Date:  2014-06-08       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.